Mark Bustoros

Finally, our paper on Genomic Profiling of Smoldering Multiple Myeloma is out @JCO @ASCO_pubs! A work that took more than 3 years but with amazing collaborations led to this large study on smoldering multiple myeloma #SMM #mmsm ascopubs.org/doi/full/10.12…

Amazing session from Dr Akhlagi from ⁦@Cornell⁩ along with Dr Mejia about the landscape of smoldering myeloma. #mmsm ⁦@PleXusComm⁩

Proud of finishing my first marathon at Châteaux du Médoc, France, on September 6.

Congrats Drs. Evelyn Orlando & Herman van Besien for participating in the @lymphoma Lymphoma Scientific Research Mentoring Program (LSRMP). Great opportunity for @HemOncFellows to workshop their research protocols w/ lymphoma experts! @WCMHemOncFellow @ev_lando @HBesien

@FaltasLab @CD_AACR @anton_gh @B_Regenberg @VineetBafna3 @Jens_Luebeck @notSoJunkDNA @ElementoLab @mischellab @roelverhaak @PGrivasMDPhD @montypal Congrats Bishoy and team!!

Excited to be part of this international collaborative effort, now published in @CD_AACR! Great to see validation of our findings on extrachromosomal DNA 📿🧬 (initially published in Nature nature.com/articles/s4158…) in an independent cohort of 595 urothelial cancer whole genomes: ✅ High prevalence of ecDNA events in UC ✅ Recurrent CCND1 amplification events within ecDNA forming SVs This work further builds on these findings investigating the Spatial-Temporal Diversity of ecDNA ✅ ecDNA can arise in flat urothelial lesions ✅ ecDNA is associated with shortened patient survival ✅ ecDNA is linked to a distinct TIME ✅ The same tumors can have both clonal and subclonal ecDNA events suggesting ongoing ecDNA biogenesis ✅ ecDNA can be detected with high specificity from sequencing urinary sediments Check out the paper here: aacrjournals.org/cancerdiscover…

A new review describes basic and translational research on the complex physiological processes of hunger, which regulate feeding habits and are influenced by socioeconomic, cultural, and behavioral factors. Read the full review: nej.md/3C8CHAn

The holidays aren’t over just yet🎄🎁🎉@WeillCornell @WCMHemOncFellow @WCM_MeyerCancer

+1q is associated with worse hematologic response rate and heme-EFS with daratumumab-based frontline therapy in AL amyloidosis. ow.ly/gPjS50Uv2cZ #clinicaltrialsandobservations #lymphoidneoplasia

Primary large B-cell lymphomas of immune-privileged sites ow.ly/Sbr150Uv2Pc #lymphoidneoplasia

sBCMA, surface antigen density, effector-to-target ratio, and TCE dose collectively mediate primary refractoriness to anti-BCMA TCE. ow.ly/V5mT50Uv0QH #immunobiologyandimmunotherapy #lymphoidneoplasia #multiplemyeloma

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Our @WCMHemOncFellow fellows at Lymphoma, Leukemia & Myeloma Congress @llmcongress in Times Square! @CaitieGribbinMD @TAkhlagh @ev_lando @HBesien @WCMLymphoma @WCMMyelomaCtr @WCMLeukemia

Big Congrats on a very well deserved recognition of Dr. @BrunoPaiva_UNAV for receiving the SASS-ARENA Foundation for Medical Research Award; Joseph Michaeli Award for Outstanding Contributions to Myeloma @llmcongress #nyc #mmsm #lysm

Excellent session on Upfront treatment in Myeloma with outstanding faculty and speakers @llmcongress @SLentzsch @JoshuaRichterMD @JMongeMD @mmejia91 , Drs Adriana Rossi & Noa Biran #mmsm @WeillCornell

That's a wrap on day 2! We explored various topics on new insights into epigenetics and lymphoma, management of mantle cell lymphoma, how to approach R/R therapy of aggressive lymphoma, and much more. Join us tomorrow for breakfast in the exhibit hall, starting at 7:30 am. #LLMCongress #LLMCongress2024 #Oncology

Great debate and overview about whether CAR-T could replace autotransplant as consolidation by Drs. Adriana Rossi & @mmejia91 @llmcongress #mmsm

EM MM, an unmet need population! @llmcongress @MarkBustoros

Hairy-cell leukemia, a rare B-cell cancer driven by a BRAF mutation and manifesting with cytopenias and splenomegaly, is responsive to purine analogue chemotherapy and to BRAF inhibitors combined with anti-CD20 antibodies. Read the full review: nej.md/3NkpIgR

@NBahlis @BloodJournal @hollyleeYJ @FrancescoMaura4 Big Congrats Nizar and the whole team!

Very excited to share with the myeloma community our latest work on the role of sBCMA and non-T cell factors on the resistance to anti-BCMA TCE ⁦@BloodJournal⁩, work led by ⁦@hollyleeYJ with Paola Neri, @FrancescoMaura4, doi.org/10.1182/blood.…

⏰ At midnight on September 20 the best rates available will end. Join us in New York City or online for the event of the year. This hybrid event is designed to meet the educational needs of those who are involved and/or interested in the treatment of patients with hematologic malignancies. What you can expect when you register and attend next month. ➡ Gain Cutting-Edge Knowledge: Review the latest clinical evidence and practical insights in hematologic malignancies. ➡ Engage with Experts: Participate in dynamic discussions with leading experts and peers, fostering valuable exchanges of ideas and best practices. ➡ Enhance Your Clinical Practice: Leave with actionable knowledge and strategies to integrate innovative treatments and advancements into daily practice, ultimately improving patient care and outcomes. ➡ Be Part of a Legacy: Celebrate 24 years of unparalleled excellence and tradition in hematology/oncology education and networking. @OncLearnNetwork @TheBMCF @LLSusa @Cure_FL @lymphoma @IMFmyeloma @WeillCornell @WCMLeukemia @CllSociety @WMIWMF @JohnPLeonardMD @jmikhaelmd @YLeyfman @MarkBustoros @MSKCancerCenter @SLentzsch @jeremyheinerich @Columbia @nyphospital @NewYorkCancer